ArticleMaterials (Basel, Switzerland)2022
Fiber Laser Welded Cobalt Super Alloy L605: Optimization of Weldability Characteristics.
Article in Materials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The present study describes the laser welding of Co-based superalloy L605 (52Co-20Cr-10Ni-15W) equivalent to Haynes-25 or Stellite-25. The influence of laser welding process input parameters such as laser beam power and welding speed on mechanical and metallurgical properties of weld joints were investigated. Epitaxial grain growth and dendritic structures were visible in the weld zone. The phase analysis results indicate the formation of hard phases like CrFeNi, CoC, FeNi, and CFe in the weld zone. These hard phases are responsible for the increase in microhardness up to 321 HV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.